Work

Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation.

Year: 2009

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/0008-5472.sabcs-09-5114

Authors: J. Baselga, J. Cortes, P. Fumoleau, T. Petrella, K. Gelmon, S. Verma, X. Pivot, G. Ross, T. Szado, L. Gianni

Institutions: Vall d'Hebron Hospital Universitari, Centre Georges François Leclerc, Sunnybrook Health Science Centre, BC Cancer Agency, Centre Hospitalier Universitaire de Besançon

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2019089983

Cites:

Cited by: 21

Related to: 10